Matasar, M. J. Et Al. 2021. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. LANCET ONCOLOGY , vol.22, no.5 , 678-689.

Matasar, M. J., Capra, M., ÖZCAN, M., Lv, F., Li, W., Yanez, E., ... Sapunarova, K.(2021). Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. LANCET ONCOLOGY , vol.22, no.5, 678-689.

Matasar, Matthew Et Al. "Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial," LANCET ONCOLOGY , vol.22, no.5, 678-689, 2021

Matasar, Matthew J. Et Al. "Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial." LANCET ONCOLOGY , vol.22, no.5, pp.678-689, 2021

Matasar, M. J. Et Al. (2021) . "Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial." LANCET ONCOLOGY , vol.22, no.5, pp.678-689.

@article{article, author={Matthew J. Matasar Et Al. }, title={Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2021, pages={678-689} }